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Background
More than 50% of JIA patients on Methotrexate (MTX)
suffer from MTX-related gastrointestinal adverse effects
– MTX intolerance (1). Nevertheless, the best approach
to treat MTX intolerance is unknown.
Aim
To compare the effect of behavioural therapy or a
switch to parenteral MTX with oral MTX on MTX
intolerance.
Methods
45 JIA patients with MTX intolerance were randomised
to receive oral MTX with anti-emetics (standard of
care), parenteral MTX or oral MTX with behavioural
therapy. Primary outcome was the occurrence of MTX
intolerance, defined as ≥5 points on a validated MISS
questionnaire, after a 3-month intervention period. Sec-
ondary outcome measures were: MTX intolerance after
6 and 12 months and the number of patients that dis-
continued MTX or switched to another treatment arm
due to intolerance.
Results
After 3 months MTX intolerance resolved in 6 (54.5%)
patients on standard of care, 4 (57.1%) patients on par-
enteral MTX and 4 (36.4%) patients on behavioural
therapy. Nine patients (30.0%) discontinued MTX or
switched to another treatment arm due to MTX intoler-
ance. Of remaining patients at 6 months, MTX intoler-
ance resolved in 2 (50%), 4 (80%) and 4 (57.1%)
patients, and at 12 months in 2 (66.7%), 4 (80%) and 3
(50%) patients in three treatment groups respectively.
All treatment arms showed a marked decrease in MTX
intolerance score on the MISS questionnaire from on
average 15 points to 6 points after 3 months.
Conclusion
Behavioural therapy and parenteral MTX were not more
effective than the standard of care in treating MTX
intolerance. Instead, all treatments strongly diminished
MTX intolerance, probably due to changes in cognitions
and self-efficacy. Physicians should not discontinue
MTX or switch to biologicals in case of MTX intoler-
ance, but rather strengthen the patient’s self-efficacy to
cope with MTX intolerance. We propose several strate-
gies to this end.
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